KRAS and neoplasm: A phase Ib/II trial evaluating the anti PD-L1 monoclonal antibody avelumab combined with the MEK1/2 inhibitor binimetinib, with or without the PARP inhibitor talazoparib (NCT03637491), including patients with advanced, KRAS + NSCLC, showed limited anti-tumor activity with a high toxicity.